

OUR SCIENCE 
TAVO SELECT ™ TAVO PRECISE ™ TAVO ELITE ™
OUR PIPELINE 
Disease Focus Pipeline
OUR TEAM 
Management Team Scientific Advisory Board
OUR PARTNERS 
Collaborations Investors
OUR COMPANY
ABOUT US 
News Join Us

info@tavotek.com





BD@tavotek.com Info@tavotek.com



NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

News

Homepage

Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

Author:
Origin:
Time of issue:2025-04-27
Views:837

Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

Author:
Origin:
Time of issue:2025-04-27
Views:837

T1330-02-09-V2.pdf

Previous: A Summary of Tavotek's Presentations at the 2025 AACR Conference

Next: Tavotek Pivotal Asset Tavo101&Tavo103 Presented at 2025 AAPS National Biotech Conference

Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets

Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania